Neal Walker - Feb 9, 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Feb 9, 2022
Transactions value $
-$45,513
Form type
4
Date filed
2/11/2022, 03:15 PM
Previous filing
Feb 3, 2022
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Sale -$45.5K -3.6K -0.29% $12.66 1.24M Feb 9, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on February 1, 2022 pursuant to preexisting sell-to-cover elections.
F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.6601 to $12.6610, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.